The following table summarizes key information about our product candidates:

Program	Indication	Drug Class	Preclinical	Clinical Phase				Marketed
				I	IIA	IIB	III
FARESTON® . (toremifene citrate 60 mg)	Advanced breast cancer	SERM
ACAPODENE® (toremifene citrate 80 mg)	Side effects of androgen deprivation therapy	SERM
ACAPODENE® (toremifene citrate 20 mg)	Prevention of prostate cancer in high risk men	SERM
Ostarine™	Sarcopenia	SARM					GTx and Merck have formed a global strategic collaboration for SARMS
	Cancer cachexia
	CKD/ESRD muscle wasting
GTx-838	Sarcopenia	SARM
GTx-758	ADT	Oral LH inhibitor
GTx-878	BPH, chronic prostatitis, rheumatoid arthritis	ERβ agonist